Introduction
============

Dose-escalated radiotherapy is an important treatment measure for lung cancers ([@b1-ol-0-0-7732]--[@b3-ol-0-0-7732]). Excellent clinical effects have been demonstrated with the treatment of intensity-modulated radiotherapy (IMRT) in conjunction with image-guided radiotherapy (IGRT) ([@b4-ol-0-0-7732]). IMRT can improve dose conformity, but it requires longer delivery time ([@b5-ol-0-0-7732]--[@b8-ol-0-0-7732]). Compared with IMRT, volumetric modulated arc therapy (VMAT) has significantly improved the delivery efficiency and treatment time ([@b7-ol-0-0-7732]).

IMRT has been previously compared with VMAT in various types of cancer ([@b7-ol-0-0-7732],[@b9-ol-0-0-7732]--[@b19-ol-0-0-7732]). Several studies have suggested that VMAT produces highly conformal dose distributions, achieves accurate dosimetric delivery and reduces treatment time ([@b7-ol-0-0-7732],[@b10-ol-0-0-7732],[@b19-ol-0-0-7732]--[@b23-ol-0-0-7732]). For lung cancer, IMRT and VMAT are currently used and compared ([@b4-ol-0-0-7732],[@b7-ol-0-0-7732],[@b10-ol-0-0-7732],[@b19-ol-0-0-7732]--[@b21-ol-0-0-7732],[@b23-ol-0-0-7732]--[@b25-ol-0-0-7732]). However, little literature exists that focuses on the comparison of IMRT and VMAT in different types of lung cancer, peripheral lung cancer and central lung cancer. In addition, there have been no studies that compare IMRT and VMAT in two different cases in central lung cancer, planning target volume (PTV) encompassing and not-encompassing the mediastinal lymphatic drainage region. In the present study, IMRT and VMAT plans were compared in quality parameters and treatment efficiency in central lung cancer and peripheral lung cancer. Three different plans were employed: Single 360° arc, part of single 360° arc and two arcs. Furthermore, IMRT and VMAT plans were compared in central lung cancer in cases of PTV encompassing or PTV not-encompassing the mediastinum.

Patients and methods
====================

### Patients and design

A total of 12 patients with lung cancer, who received radical radiotherapy treatment in the First Hospital Affiliated to Xi\'an Jiao Tong University (Xi\'an, China), 12 patients were enrolled in the study from August 2011 to August 2017. Patients with peripheral lung cancer and central lung cancer were randomly selected. All patients were staged according to the modified 1997 American Joint Committee on Cancer (AJCC) staging system. The patient characteristics were listed in [Table I](#tI-ol-0-0-7732){ref-type="table"}. The present study was approved by the Ethics Committee of the First Hospital Affiliated to Xi\'an Jiao Tong University (Xi\'an, China) and written consent was obtained from the patients.

### PTV delineation and dose prescription

For small cell lung cancer (SCLC), PTV was designed as Gross tumor volume (GTV) plus 1.5 cm margin, including the ipsilateral hilum and bilateral mediastinum, and excluding the contralateral hilum. For non-NSCLC, GTV encompassed the gross primary tumor and metastatic lymph nodes (LNs) ≥1 cm or hypermetabolic on PET scan. Clinical target volume (CTV) typically encompasses the GTV plus 1--1.5 cm margin. PTV added a 0.5--0.8 cm margin on CTV to account for set-up uncertainties and respiratory motion. Respiratory tracking or 4D scanning allow for decreased PTV margins. Each peripheral lung tumor was contoured by two physicians. The PTV of central lung cancer was defined as GTV (including primary cancer and metastatic lymph nodes) plus a margin of 1.5 cm in lateral, anterior and craniocaudal direction, plus the area within 2 cm of the proximal bronchial tree, which includes the lower trachea, carina, mainstem bronchi, and the lobar bronchi. Internal target volume (ITV) was used to encompass all mobile tumor positions in breathing cycles for treatment accuracy. For each patient, IMRT plans and VMAT plans were generated simultaneously and compared. 60 Gy was prescribed as the median dose applied to the PTV.

### Treatment planning and optimizing IMRT

The IMRT optimization was performed by applying Direct Machine Parameter Optimization (DMPO) algorithm in our treatment planning system (Pinnacle3; Philips Radiation Oncology Systems, Fitchburg, MA, USA), as previously described ([@b13-ol-0-0-7732]). For each plan, 5 or 7 coplanar beams were used depending on the tumor location. In the plan generation, the maximum iterations and maximum number of all segments in the plan optimizing were 50 and 80. The maximum monitor units (MUs) and segments area were 5 MU and 5 cm^2^, respectively. Plans were generated for the Elekta Beam Modulator with 10 MV.

### Single-arc (SA)-VMAT

The VMAT planning was conducted applying the SmartArc planning algorithm in Pinnacle3 9.2 (research version; Philips Radiation Oncology Systems). The optimizer (single arc) was constrained to use one single 360° arc which consisted of 90 control points. The arc was represented by 89 beams each separated by 4°, which started at 181° and ended at 180°. The accelerator-used automatic dose rate was selected for each individual segment of the arc. Plans were generated with 10 MV.

### Partial-arc (PA)-VMAT

The plans were optimized in the same planning system mentioned above. A 180--200° partial arc was generated for standardization across the studied cased with the range coinciding with the tumor location while avoiding as much of the contralateral lung as possible, which started between 170--180° and ended between 0--10°. The arc was represented by 44--49 beams each separated by 4°.

### Dual 2PA-VMAT

The plans were generated with two partial arcs, and each partial arc parameter was the same as the one in the PA-VMAT.

### Plan evaluation

The quality of plans was evaluated by three radiation oncologists. Dose volume histograms (DVHs) and the corresponding dose distributions of plans were independently reviewed by each oncologist. A total of 95% of target volume should be encompassed by 95% of the prescribed dose. PTV coverage was evaluated by using Dmax, Dmin, Dmean, the heterogeneity index (HI) and the conformality index (CI).
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D2, D98 and D50% represent the dose of 2, 98 and 50% target volume. Values of HI closer to 0 indicate greater dose homogeneity within the volume of PTV, while large values indicate more heterogeneous dose distribution.
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*V~T,\ ref~* = volume of target receiving a dose equal to or greater than the reference dose, *V~T~* = volume of target, *V~ref~* = volume receiving a dose equal to or greater than the reference dose (treated volume). The closer the value of CI to 1.0, the better the dose conformity.

### Statistical analysis

The SAS 21.0 software (SAS Institute Inc., Cary, NC, USA) was used to analyze and compare the data with randomized block design. The data of each treatment group were analyzed with normality test (Shapiro-Wilk test) and homogeneity of variance test (Levene test). Analysis of variance and Fisher\'s least significant test (LSD-t) were used when data obeyed normal distribution and homogeneity of variance. If the data did not obey the normal distribution, the variance was not uniform, or the data did not obey the normal distribution following conversion, the rank sum test (Friedman\'s test, also called the M-test) was used for the randomized block design data; if the rank sum test was statistically significant, this indicated that the mean of multiple populations was different or not equal. Then, Friedman\'s test and multiple comparison non-parametric tests were used. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Dosage comparison between VMAT and IMRT plans in peripheral lung cancer

[Fig. 1](#f1-ol-0-0-7732){ref-type="fig"} illustrates the dose-volume histogram (DVH) and dose distributions of IMRT and VMAT plans of a patient with peripheral lung cancer. [Figs. 2](#f2-ol-0-0-7732){ref-type="fig"} and [3](#f3-ol-0-0-7732){ref-type="fig"} illustrate the CI, HI and organ at risk (OAR) dosage of each patient. The average delivery times for IMRT plans and VMAT plans were 10.5 and 6.1 min respectively. VMAT plans generated larger numbers of MU compared to IMRT.

[Table II](#tII-ol-0-0-7732){ref-type="table"} illustrated the dosage difference between VMAT and IMRT plans in peripheral lung cancer. In peripheral lung cancer, there was no significant difference of CI and HI of PTV among IMRT, SA-VMAT, PA-VMAT, and 2PA-VMAT plans ([Figs. 1](#f1-ol-0-0-7732){ref-type="fig"} and [2](#f2-ol-0-0-7732){ref-type="fig"}). The target area is far away from the spinal cord and heart, therefore the received dose of the spinal cord and heart were low; the IMRT plan achieved superior sparing of spinal cord compared with the VMAT plans, and the radiation dose of the spinal cord was the highest in the SA-VMAT plan. IMRT plans exhibited significantly improved sparing of V20, V30 of total lungs and Dmean, V30 of ipsilateral lung compared with SA-VMAT, PA-VMAT and 2PA-VMAT plans. PA-VMAT and 2PA-VMAT exhibited significantly better Dmean, V5 (%), V10 (%) of lung-contralateral compared with the IMRT plan. V5 (%) of lung-all of SA-VMAT was higher compared with PA-VMAT. V5 (%) of lung-all of IMRT plan was higher compared with SA-, PA- and 2PA-VMAT; V20, V30 (%) of lung-all of SA-, PA-, 2PA-VMAT were higher compared with IMRT. V5 (%) of lung-ipsilateral of IMRT was higher compared with SA-, PA-, 2PA-VMAT. IMRT plans also exhibited significantly improved sparing of Dmean of contralateral lung than PA- and 2PA-VMAT plans ([Fig. 3](#f3-ol-0-0-7732){ref-type="fig"}).

### Dosage comparison between VMAT and IMRT plans in central lung cancer in which the target volume does not encompass the mediastinal lymphatic drainage region

For central lung cancer, it remains unanswered when PTV needs to encompass the mediastinal lymphatic drainage region. It is hypothesized that this depends on the tumor pathological type and whether there exist metastatic mediastinal lymph nodes or not. For SCLC, PTV needs to encompass the mediastinal lymphatic drainage region. For NSCLC, if there are metastatic mediastinal lymph nodes, PTV needs to encompass the metastatic lymph nodes. If not, PTV does not encompass it. [Fig. 4](#f4-ol-0-0-7732){ref-type="fig"} illustrates the dose-volume histogram DVH and dose distributions of IMRT and VMAT plans of a patient with central lung cancer whose PTV did not encompass the mediastinum. [Figs. 5](#f5-ol-0-0-7732){ref-type="fig"} and [6](#f6-ol-0-0-7732){ref-type="fig"} illustrate the CI, HI and OAR dosage of each patient.

In the case of PTV not encompassing the mediastinum in central lung cancer, [Table III](#tIII-ol-0-0-7732){ref-type="table"} illustrated the dosage difference between VMAT and IMRT plans. SA-VMAT exhibited significantly superior CI compared with IMRT, PA- 2PA-VMAT. SA- and 2PA-VMAT exhibited significantly superior HI than IMRT and PA-VMAT. Dmax of PTV in SA-VMAT and 2PA was significantly higher compared with IMRT and PA-VMAT. Dmin of PTV in PA-VMAT was significantly lower compared with IMRT and SA-VMAT. V30, V40 (%) of heart of SA-VMAT were higher compared with IMRT, PA- and 2PA-VMAT in most cases. V5, V10, V20 (%) of lung-all of IMRT were higher compared with SA-, PA-, and 2PA-VMAT in most cases. V10 (%) of lung-all of 2PA-VMAT was less compared with IMRT, SA- and PA-VMAT.

### Dosage comparison between VMAT and IMRT plans in central lung cancer in which the target volume encompasses the mediastinal lymphatic drainage region

In central lung cancer, in case of either SCLC or positive metastatic mediastinal lymph nodes, PTV needs to encompass the mediastinum. [Fig. 7](#f7-ol-0-0-7732){ref-type="fig"} illustrated the DVH and dose distributions of IMRT and VMAT plans of a patient with central lung cancer whose PTV encompasses the mediastinum. [Figs. 8](#f8-ol-0-0-7732){ref-type="fig"} and [9](#f9-ol-0-0-7732){ref-type="fig"} illustrate the CI, HI and OAR dosage of each patient.

In the case of PTV encompassing the mediastinum in central lung cancer, [Table IV](#tIV-ol-0-0-7732){ref-type="table"} illustrated the dosage comparison between VMAT and IMRT plans. 2PA-VMAT exhibited superior HI and CI compared with IMRT, SA- and PA-VMAT in most cases, but V40 (%) of heart in 2PA-VMAT was higher compared with IMRT, SA- and PA-VMAT. V5, V30 (%) of lung-all in 2PA-VMAT was higher compared with IMRT. By contrast, V20 (%) of lung-all in 2PA-VMAT was less compared with IMRT, SA-, and PA-VMAT. V5, V10 (%) of lung-contralateral in SA-, PA-, and 2PA-VMAT was higher compared with IMRT, while V20, V30 (%) of lung-contralateral in 2PA-VMAT was less compared with IMRT.

In conclusion, in peripheral lung cancer, V5 (%) of the lung in PA-VMAT was less compared with IMRT, SA-, and 2PA-VMAT. V30 (%) of the lung in IMRT was less compared with SA-, PA- and 2PA-VMAT. In the case of PTV not encompassing the mediastinum in central lung cancer, the CI and HI of SA-VMAT was improved compared with IMRT, PA-, and 2PA-VMAT; the received dose of heart in SA-VMAT was higher compared with IMRT, PA- and 2PA-VMAT. V30 (%) and V5 (%) of the lung in IMRT was higher compared with SA-, PA- and 2PA-VMAT; V10 (%) of the lung in 2PA was less compared with IMRT, SA- and PA-VMAT. In the case of PTV encompassing the mediastinum in central lung cancer, the HI and CI of 2PA was improved compared with IMRT, SA- and PA-VMAT. The received dose of heart in 2PA was higher compared with IMRT, SA- and PA-VMAT. V30 (%) and V5 (%) of the lung in 2PA-VMAT was higher compared with IMRT, SA- and PA-VMAT. V20 (%) of the lung in 2PA was lower compared with IMRT, SA- and PA-VMAT.

Discussion
==========

The differences of dosimetry and clinical characters between VMAT and IMRT have been studied by many studies ([@b9-ol-0-0-7732]--[@b16-ol-0-0-7732],[@b19-ol-0-0-7732],[@b25-ol-0-0-7732],[@b27-ol-0-0-7732]--[@b33-ol-0-0-7732]) and VMAT technique has displayed superiority in different types of solid tumors compared with IMRT, especially tumors with complicated target volume ([@b1-ol-0-0-7732]--[@b17-ol-0-0-7732]). The present study compared dosimetric differences and treatment efficiency between IMRT and three kinds of VMAT plans in the following three situations: Peripheral lung cancer, PTV not encompassing the mediastinal lymphatic drainage region in central lung cancer, and PTV encompassing the mediastinal lymphatic drainage region in central lung cancer. To our knowledge, this is the first study to report dosimetric differences between IMRT, SA-VMAT, PA-VAMT and 2PA-VMAT plans in these three situations.

In peripheral lung cancer, there was no significant difference of CI and HI among IMRT, SA-VMAT, PA-VMAT, and 2PA-VMAT plans. This is because the targets were small and far away from normal organs, and radiotherapy plans and dose requirement were easily achieved, resulting in similar CI and HI for each plan. Because spinal cords and hearts were far from targets, they received less radiation. V5 (%) of total lungs in SA-VMAT plans were higher compared with PA-VMAT plans, because the radiation regions in SA-VMAT plans were larger compared with PA-VMAT plans. V5 of total lungs and contralateral lungs in the IMRT plan were higher compared with SA-, PA- and 2PA-VMAT plans. V5 of ipsilateral lungs in IMRT plans were lower compared with SA-, PA- and 2PA-VMAT plans. This was because tumors in most cases located in the lower lobes, so the radiation fields were relatively concentrated and focused to the contralateral lung, which led to higher V5 of contralateral lung and then led to higher V5 of total lungs in IMRT plans. V20 and V30 of total lungs in SA-, PA- and 2PA-VMAT plans were higher compared with IMRT plans. This was because tumors in most cases located near the chest wall, so VMAT plans required a larger range of radiation angles, which resulted in more dispersed dose distribution of 20 and 30 Gy.

In the case of PTV not encompassing the mediastinum in central lung cancer, SA-VMAT plans exhibited better CI and HI than IMRT, PA- and 2PA-VMAT plans. Because the target volumes were relatively large and the target located in the center, the incidence angles of IMRT, PA- and 2PA-VMAT plans were smaller compared with SA-VMAT. However, V30 and V40 of heart in SA-VMAT plans were higher compared with IMRT, PA- and 2PA-VMAT plans. Because the incidence angle of SA-VMAT plan was 360 degree and the target located near the heart, it resulted in the heart receiving a higher radiation dose. The spinal cord was far away from the target thus it received less radiation dose. In most cases, V5, V10 and V20 of total lungs in IMRT plans were higher compared with SA-, PA- and 2PA-VMAT plans, because the target was in the center and the radiation fields of IMRT plans were relatively concentrated. The concentrated radiation fields focused to the ipsilateral lung and resulted in a higher dose. V10 and V20 of total lungs in 2PA-VMAT plans were decreased compared with IMRT, SA- and PA-VMAT plans. The differences of radiation dose of ipsilateral lungs and contralateral lungs were slight.

In the case of PTV encompassing the mediastinum in central lung cancer, the 2PA-VMAT plan in most cases exhibited improved CI and HI compared with IMRT, SA- and PA-VMAT plans. Because the target volume in this case was the largest and the targets were located in the center or near the center, this increased the difficulty of planning. The 2PA-VMAT plan possesses the most optimized incidence angles; therefore it achieved the best CI and HI. Because the optimized incidence angles in 2PA-VMAT plans induced the largest radiation area of heart, V40 of heart in 2PA-VMAT plans were higher compared with IMRT, SA- and 2PA-VMAT plans. Since the spinal cord was near the target, planning optimization for 2PA-VMAT yielded the radiation dose of spinal cord within the tolerance range. V5, V30 of total lungs in 2PA-VMAT plans were higher compared with the IMRT plan, whereas V20 of total lungs in 2PA-VMAT plans were lower compared with IMRT, SA- and PA-VMAT plans. This is because more incidence angles in the 2PA-VMAT plan resulted in increased areas of low dose in contralateral lung and total lungs. In addition, more optimized incidence angles in the 2PA-VMAT plan resulted in lower V20 of total lungs and similar radiation of ipsilateral lung. V5 and V10 of contralateral lungs in SA-, PA- and 2PA-VMAT plans were higher compared with the IMRT plan, whereas V20 and V30 of contralateral lungs in SA-, PA- and 2PA-VMAT plans were lower compared with the IMRT plan. The reason was the same as the dose comparison of total lungs.

Is the present data demonstrate that it may be necessary to classify the radiotherapy plans of lung cancer into three categories, including peripheral lung cancer, PTV not encompassing mediastinum of central lung cancer, and PTV encompassing mediastinum of central lung cancer. Each of IMRT, SA-VMAT, PA-VMAT, and 2PA-VMAT plan has its individual advantages and therefore it is important to employ different planning techniques regarding to different situations. In peripheral lung cancer, V5 (%) of the lung in PA-VMAT was low. V20 (%) and V30 (%) of the lung in IMRT was low. Different techniques may be used according to different requirements of lung dose. In the case of PTV not encompassing the mediastinum in central lung cancer, the HI and CI of SA-VMAT was the best, but with a relatively high heart dose. The received dose of lung was the highest in the IMRT plan. V10 (%) of the lung in 2PA-VMAT was the lowest. If the pulmonary function is poor, it may be better to employ 2PA-VMAT instead of IMRT. In case of PTV encompassing mediastinum in central lung cancer, if the PTV is big, it is hard to decide on a good radiotherapy plan. The HI and CI of 2PA-VMAT were good but with high heart dose. V5 (%) and V30 (%) of the lung in 2PA-VMAT were high, whereas V20 (%) of the lung was low. Therefore, it may crucial to employ different planning techniques considering different OAR requirements.

Radiation-induced pneumonitis (RIP) is one of the most common and serious complications following radiation of thoracic malignancies, which produces a considerable effect on patient morbidity, even leading to death. The incidence of RIP is closely correlated with the irradiation dose that the lungs received ([@b28-ol-0-0-7732]). Studies have suggested that the dosimetric parameters of the lung DVH, such as mean lung dose, V20 and V30 of lung, are direct factors which can affect RIP incidence ([@b34-ol-0-0-7732]--[@b37-ol-0-0-7732]).

According to Schallenkamp *et al* ([@b38-ol-0-0-7732]), a study of a 92-patient cohort, V10/13/15 was also significantly correlated to RIP. Wang *et al* ([@b39-ol-0-0-7732]) demonstrated that V5 of both lung lobes was the only parameter predicting the incidence of RIP (≥grade 2) in NSCLC patients. The present results suggested that VMAT plans obviously delivered low irradiation dose to a larger volume of lung than IMRT, so the VMAT technique may increase RIP incidence more than IMRT in peripheral lung cancer and PTV not encompassing mediastinum of central lung cancer.

Multiple studies have confirmed that VMAT has a significantly shorter delivery time than IMRT ([@b7-ol-0-0-7732]). The present study also demonstrated that VMAT had a significant advantage of delivery efficiency and treatment time. Improved treatment efficiency of VMAT yielded less scatter dose from reducing MU, which may reduce secondary malignancies. Less treatment time also enhances patient comfort and satisfaction and decreases the intra-fraction variation.

With respect to the present study, no one planning technique was demonstrated to be superior in all aspects. IMRT and 2PA-VMAT plans achieved superior conformal plans in these three kinds of situations compared with the other plans. As for OARs sparing, the four planning techniques could achieve superior sparing of different organs. SA/PA/2PA-VMAT plan were more effective at dose delivery than other plans.

Several studies have suggested that the VMAT plan is better than the IMRT plan in lung cancer. Jiang *et al* ([@b28-ol-0-0-7732]) reported that the VMAT plan gets superior PTV coverage than IMRT plans for locally advanced lung cancer. Jiang *et al* ([@b28-ol-0-0-7732]) demonstrated that V20, V30 and MLD of the total and contra-lateral lungs in VMAT plans were significantly lower compared with IMRT plans. Other studies have demonstrated that VMAT plans achieved the most objectives on target volumes and OARs for stage III NSCLC ([@b27-ol-0-0-7732],[@b29-ol-0-0-7732]). There may be two reasons which lead to the different results. One reason may be related to different situations of target volume. For example, in the present study, different results were obtained between the case of PTV encompassing mediastinal lymphatic drainage region and the case of PTV not encompassing the mediastinal lymphatic drainage region in central lung cancer. The other reason may be related to different planning system, different accelerator and the effort on planning. The plan quality depends heavily on the amount of effort spent on the planning and planner\'s experience ([@b25-ol-0-0-7732],[@b40-ol-0-0-7732]). One major challenge of VMAT plans is that VMAT requires a much longer time to optimize compared with IMRT. The long optimization time may introduce more variations in plan quality due to limits on planners\' time and effort ([@b9-ol-0-0-7732],[@b11-ol-0-0-7732],[@b14-ol-0-0-7732]). Therefore, it is more difficult to assure high-quality of treatment plans for VMAT than for IMRT.

Concrete analysis should be performed according to concrete circumstance of each patient to make the best plan. The suitability of the planning technique could vary depending on the staging, tumor size, location of tumor, OARs and the dose-tolerance criteria. However, the data from the present study has limitations, because the small numbers of patients enrolled renders the results less reliable. In addition, for IMRT, alternate planning techniques using more beams could have bene attempted; however, incorporation of such variation could increase the plan complexity at cost of treatment time. Further clinical investigation is required in order to fully address these concerns.

In conclusion, the present results suggest that it may be necessary to classify the radiotherapy plans of lung cancer into three categories, including peripheral lung cancer, PTV not encompassing mediastinum of central lung cancer, and PTV encompassing mediastinum of central lung cancer. In the present study, the dosimetric differences and treatment efficiency were compared between IMRT and VMAT plans in three types of cases. Each of IMRT, SA-VMAT, PA-VMAT, and 2PA-VMAT plan had individual advantages, and it may be crucial to employ different planning techniques in different situations. Different techniques may be used according to different requirements of lung dose. If the pulmonary function is poor, it may be better to employ 2PA-VMAT instead of IMRT. In case of PTV encompassing mediastinum in central lung cancer, if the PTV is large, it may be hard to decide on a good radiotherapy plan. Additionally, it may be important to employ different planning techniques considering different OAR requirements. The suitability of the planning technique could vary depending on the staging, tumor size, location of tumor, OARs as well as the dose-tolerance criteria. Concrete analysis should be made according to concrete circumstance of each patient to make the best plan for radiotherapy of lung cancer.

This study was supported by the National Natural Science Foundation of China (grant nos. 81772793/H1621, 31201060/C0709, 30973175/H1621 and 81172490/H1621), the Program for New Century Excellent Talents in University (grant no. NCET-12-0440), the Scientific and Technological Research Foundation of Shaanxi Province (grant no. 2012K13-01-06), the Research Foundation of Health Department of Shaan\'xi Province (grant no. 2010D41), the Qing Nian Jiao Shi Gen Zong Ji Hua of Xi\'an Jiaotong University, and a Clinical Research Award of the First Affiliated Hospital of Xi\'an Jiaotong University (grant no. XJTU1AHCR2014-041).

![Isodose curves of IMRT plan and 2PA-VMAT plan in peripheral lung cancer. (A) Isodose curves of IMRT plan. (B) Isodose curves of SA-VMAT plan. (C) Isodose curves of PA-VMAT plan. (D) Isodose curves of 2PA-VMAT plan. In peripheral lung cancer, both IMRT plan and VMAT plan exhibited satisfying prescribed tumor target coverage and OAR sparing. However, 2PA-VMAT displayed improved PTV coverage compared with IMRT. 2PA-VMAT exhibited better sparing of spinal cord, lung-all, and lung-contralateral compared with IMRT, while IMRT exhibited better heart and lung-ipsilateral sparing compared with 2PA-VMAT. IMRT had better dose conformity and homogeneity. IMRT, intensity-modulated radiation therapy; VMAT, volumetric modulated arc therapy; 2PA, double partial arc; PA, partial arc; SA, single arc; OAR, organs-at-risk.](ol-15-03-3735-g02){#f1-ol-0-0-7732}

![Line charts display the comparison of (A) CI and (B) HI between VMAT and IMRT plans in 6 patients (indicated by different lines) with peripheral lung cancer. The horizontal axis represents the four different plans. The vertical axis represents values of CI and HI. CI, conformity index; HI, homogeneity index; VMAT, volumetric modulated arc therapy; IMRT, intensity-modulated radiation therapy; PA, partial arc; SA, single arc; 2PA, double partial arc.](ol-15-03-3735-g03){#f2-ol-0-0-7732}

![Line charts display the comparison of different dosimetric parameters (indicated by different lines) between VMAT and IMRT plans in 6 patients (indicated by A-a-F-f) with peripheral lung cancer. The horizontal axis represents the four different plans. The vertical axis represents the dose size. For each case, the capital letters show the unit for dose size in cGy, and the small letters show the unit for dose size in %. VMAT, volumetric modulated arc therapy; IMRT, intensity-modulated radiation therapy; cGy, centigray; PA, partial arc; SA, single arc; 2PA, double partial arc.](ol-15-03-3735-g04){#f3-ol-0-0-7732}

![Isodose curves of 2PA-VMAT and IMRT plans in central lung cancer in which the target volume does not encompass the mediastinal lymphatic drainage region. (A) Isodose curves of IMRT plan. (B) Isodose curves of SA-VMAT plan. (C) Isodose curves of PA-VMAT plan. (D) Isodose curves of 2PA-VMAT plan. In central lung cancer, when PTV does not encompass the mediastinum, there was no significant difference in PTV coverage between the IMRT and 2PA-VMAT plans. 2PA-VMAT exhibited better spinal cord sparing, and better dose conformity and homogeneity. 2PA, double partial arc; VMAT, volumetric modulated arc therapy; IMRT, intensity-modulated radiation therapy; PA, partial arc; SA, single arc; PTV, planning target volume.](ol-15-03-3735-g05){#f4-ol-0-0-7732}

![Line charts display the comparison of (A) CI and (B) HI between VMAT and IMRT plans in 4 patients with central lung cancer in which the target volume encompasses the mediastinal lymphatic drainage region. The horizontal axis represents the four different plans. The vertical axis represents values of CI and HI. CI, conformity index; HI, homogeneity index; VMAT, volumetric modulated arc therapy; IMRT, intensity-modulated radiation therapy; PA, partial arc; SA, single arc; 2PA, double partial arc.](ol-15-03-3735-g06){#f5-ol-0-0-7732}

![Line charts display the comparison of different dosimetric parameters (indicated by different lines) between VMAT and IMRT plans in 4 patients (indicated by A-a-D-d,) with central lung cancer in which the target volume encompasses the mediastinal lymphatic drainage region. The horizontal axis represents the four different plans. The vertical axis represents dose size. In each case, the capital letters show the unit for dose size in cGy, and the small letters show the unit for dose size in %. VMAT, volumetric modulated arc therapy; IMRT, intensity-modulated radiation therapy; cGy, centigray; PA, partial arc; SA, single arc; 2PA, double partial arc.](ol-15-03-3735-g07){#f6-ol-0-0-7732}

![Isodose curves of 2PA-VMAT and IMRT plans in central lung cancer in which the target volume encompasses the mediastinal lymphatic drainage region. (A) Isodose curves of IMRT plan. (B) Isodose curves of SA-VMAT plan. (C) Isodose curves of PA-VMAT plan. (D) Isodose curves of 2PA-VMAT plan. In central lung cancer, when PTV encompasses the mediastinum, 2PA-VMAT exhibited improved PTV coverage compared with IMRT. IMRT exhibited better sparing of spinal cord, lung-all, lung-ipsilateral, and lung-contralateral compared with 2PA-VMAT. In addition, IMRT exhibited better dose conformity and homogeneity. 2PA, double partial arc; VMAT, volumetric modulated arc therapy; IMRT, intensity-modulated radiation therapy; PA, partial arc; SA, single arc; PTV, planning target volume.](ol-15-03-3735-g08){#f7-ol-0-0-7732}

![Line charts display the comparison of (A) CI and (B) HI between VMAT and IMRT plans in 4 patients (indicated by different lines) with central lung cancer in which the target volume does not encompass the mediastinal lymphatic drainage region. The horizontal axis represents the four different plans. The vertical axis represents values of CI and HI. CI, conformity index; HI, homogeneity index; VMAT, volumetric modulated arc therapy; IMRT, intensity-modulated radiation therapy; PA, partial arc; SA, single arc; 2PA, double partial arc.](ol-15-03-3735-g09){#f8-ol-0-0-7732}

![Line charts display the comparison of different dosimetric parameters (indicated by different lines) between VMAT and IMRT plans in 4 patients (indicated by Aa-Dd) with central lung cancer in which the target volume does not encompass the mediastinal lymphatic drainage region. The horizontal axis represents the four different plans. The vertical axis represents dose size. In each case, the capital letters show the unit for dose size in cGy, and the small letters show the unit for dose size in %. VMAT, volumetric modulated arc therapy; IMRT, intensity-modulated radiation therapy; cGy, centigray; PA, partial arc; SA, single arc; 2PA, double partial arc.](ol-15-03-3735-g10){#f9-ol-0-0-7732}

###### 

Characteristics of the patients (n=12).

  Characteristics                                       Total
  ----------------------------------------------------- ---------------
  Age (years)                                           
    Median                                              54
    Range                                               40--68
  Sex (no. of patients)                                 
    Male                                                10
    Female                                              2
  Disease stage                                         
    II                                                  6
    IIIa                                                4
    IIIb                                                2
  Central or peripheral lung cancer (no. of patients)   
    Central                                             6
    Peripheral                                          6
  PTV volumes (cm^3^)                                   
    Median                                              95.81
    Range                                               48.78--203.97
  PTV, planning target volume.                          

###### 

Dosage comparison between VMAT and IMRT plans in peripheral lung cancer.

  Peripheral lung cancer            IMRT (mean ± SD)                                             SA-VMAT (mean ± SD)   PA-VMAT (mean ± SD)                                        2PA-VMAT (mean ± SD)
  --------------------------------- ------------------------------------------------------------ --------------------- ---------------------------------------------------------- ----------------------------------------------------------
  PTV Dmax                          6,654.70±9.55^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^   7,013.00±7.02         7,042.40±7.01                                              6,951.40±6.83
  PTV Dmin                          5,279.20±5.22                                                5,281.40±5.21         5,151.50±5.08                                              5,217.60±5.17
  PTV D100 (cGy)                    5,279.20±5.07                                                5,281.40±5.01         5,151.50±5.03                                              5,217.60±5.16
  PTV D mean (cGy)                  6,350.00±6.35^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^   6,616.40±6.11         6,558.70±6.01                                              6,560.80±6.21
  PTV D98 (cGy)                     5,860.00±5.11                                                5,790.00±5.13         57,770.00±5.07                                             5,775.00±5.14
  PTV D95 (cGy)                     6,000.00±5.56                                                6,000.00±5.61         6,000.00±5.52                                              6,000.00±5.59
  PTV D50 (cGy)                     6,387.00±6.11^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^   6,687.00±6.23         6,654.00±6.33                                              6,627.00±6.22
  PTV D2 (cGy)                      6,557.00±6.15^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^   6,971.00±6.32         6,967.00±6.42                                              6924±6.25
  Heart V30^e^ (%)                  8.65±0.02^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^       11.85±0.03            11.94±0.03                                                 9.51±0.02^[c](#tfn3-ol-0-0-7732){ref-type="table-fn"}^
  Heart V40^e^ (%)                  3.19±0.00^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^       5.73±0.01             5.62±0.01                                                  4.55±0.00
  Spinalcord D max (cGy)            1,330.3±1.32^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^    1,692.9±1.43          985.7±1.01                                                 1,129.7±1.13
  Spinalcord D~5~ (cGy)             1,161±1.11^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^      1586±1.15             900±0.91^[b](#tfn2-ol-0-0-7732){ref-type="table-fn"}^      1,025±1.09^[c](#tfn3-ol-0-0-7732){ref-type="table-fn"}^
  Lung all V5^e^ (%)                34.93±0.03^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^      37.87±0.03            22.64±0.02^[b](#tfn2-ol-0-0-7732){ref-type="table-fn"}^    26.22±0.02^[c](#tfn3-ol-0-0-7732){ref-type="table-fn"}^
  Lung all V10^e^ (%)               15.03±0.01                                                   22.23±0.01            14.1±0.00^[b](#tfn2-ol-0-0-7732){ref-type="table-fn"}^     14.59± 0.01^[c](#tfn3-ol-0-0-7732){ref-type="table-fn"}^
  Lung all V20^e^ (%)               7.72±0.00^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^       9.63±0.01             9.17±0.01                                                  9.21±0.01
  Lung all V30^e^ (%)               5.32±0.01^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^       6.37±0.01             6.69±0.01                                                  6.38±0.01
  Lung all D mean (cGy)             647.20±0.61                                                  761.80±0.71           641.60±0.62^[b](#tfn2-ol-0-0-7732){ref-type="table-fn"}^   657.30±0.63^[c](#tfn3-ol-0-0-7732){ref-type="table-fn"}^
  Lung-ipsilateral D mean (cGy)     1,072.40±1.02^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^   1,235.60±1.21         1,215.20±1.20                                              1,209.70±1.19
  Lung-ipsilateral V5 (%)           37.92±0.03^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^      41.74±0.04            41.49±0.04                                                 41.64±0.04
  Lung-ipsilateral V10 (%)          30.49±0.03                                                   33.62±0.03            32.51±0.03                                                 33.38±0.03
  Lung-ipsilateral V20 (%)          17.87±0.01^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^      22.22±0.02            21.22±0.02                                                 21.31±0.02
  Lung-ipsilateral V30 (%)          12.31±0.01^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^      14.74±0.01            15.47±0.01                                                 14.77±0.01
  Lung-contralateral D mean (cGy)   323.60±0.32^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^     401.10±0.04           205.00±0.02^[b](#tfn2-ol-0-0-7732){ref-type="table-fn"}^   236.90±0.02^[c](#tfn3-ol-0-0-7732){ref-type="table-fn"}^
  Lung-contralateral V5 (%)         32.66±0.03^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^      34.93±0.03            8.28±0.00^[b](#tfn2-ol-0-0-7732){ref-type="table-fn"}^     14.48± 0.01^[c](#tfn3-ol-0-0-7732){ref-type="table-fn"}^
  Lung-contralateral V10 (%)        3.25±0.00^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^       13.56±0.00            0.09±0.00^[b](#tfn2-ol-0-0-7732){ref-type="table-fn"}^     0.28±0.00^[c](#tfn3-ol-0-0-7732){ref-type="table-fn"}^
  Lung-contralateral V20 (%)        0.00±0.00                                                    0.05±0.00             0.00±0.00                                                  0.00±0.00
  Lung-contralateral V30 (%)        0.00±0.00                                                    0.00±0.00             0.00±0.00                                                  0.00±0.00
  HI                                0.11±0.00^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^       0.18±0.00             0.18±0.00                                                  0.17±0.00
  CI                                0.69±0.00^[a](#tfn1-ol-0-0-7732){ref-type="table-fn"}^       0.50±0.00             0.51±0.00                                                  0.52±0.00

P\<0.05 compared with 2PA-VMAT plan

P\<0.05 compared with SA-VMAT plan

P\<0.05 compared with SA-VMAT plan. IMRT, intensity-modulated radiation therapy; VMAT, volumetric modulated arc therapy; SA, single arc; PA, partial arc; 2PA, double partial arc; SD, standard deviation; PTV, planning target volume; cGy, centigray; HI, homogeneity index; CI, conformity index.

###### 

Dosage comparison between VMAT and IMRT plans in central lung cancer in which the target volume does not encompass the mediastinal lymphatic drainage region.

  PTV not encompassing the mediastinal lymphatic drainage region in central lung cancer   IMRT (mean ± SD)                                             SA-VMAT (mean ± SD)   PA-VMAT (mean ± SD)                                       2PA-VMAT (mean ± SD)
  --------------------------------------------------------------------------------------- ------------------------------------------------------------ --------------------- --------------------------------------------------------- ------------------------------------------------------------
  PTV Dmax                                                                                6,620.50±6.55                                                6,932.80±6.67         7,015.60±7.05                                             6,594.00±6.56
  PTV Dmin                                                                                5,192.20±5.55                                                5,012.90±5.05         4,897.80±4.87                                             5,164.50±5.11
  PTV D100 (cGy)                                                                          5,192.20±5.09                                                5,012.90±5.00         4,897.80±4.79                                             5,164.50±5.09
  PTV D mean (cGy)                                                                        6,222.90±6.21                                                6,506.90±6.50         6,573.30±6.53                                             6,191.60±6.09^[c](#tfn6-ol-0-0-7732){ref-type="table-fn"}^
  PTV D98 (cGy)                                                                           5,800.00±5.79                                                5,770.00±5.78         5,700.00±5.71                                             5,820.00±5.88
  PTV D95 (cGy)                                                                           6,000.00±5.58                                                6,000.00±5.59         6,000.00±5.61                                             6,000.00±5.63
  PTV D50 (cGy)                                                                           6,232.00±6.33                                                6,232.00±6.35         6,647.00±6.65                                             6,203.00±6.22
  PTV D2 (cGy)                                                                            6,459.00±6.49                                                6,788.00±6.95         6,901.00±6.92                                             6,397.00±6.41
  Heart V30^e^ (%)                                                                        14.85±0.02                                                   16.00±0.02            25.01±0.02^[b](#tfn5-ol-0-0-7732){ref-type="table-fn"}^   11.63±0.02^[c](#tfn6-ol-0-0-7732){ref-type="table-fn"}^
  Heart V40^e^ (%)                                                                        5.70±0.02                                                    6.75±0.02             6.58±0.02                                                 5.20±0.02
  Spinalcord D max (cGy)                                                                  4,009.60±4.02^[a](#tfn4-ol-0-0-7732){ref-type="table-fn"}^   4,389.30±4.02         4,297.70±4.02                                             3,796.00±3.72^[c](#tfn6-ol-0-0-7732){ref-type="table-fn"}^
  Spinalcord D~5~ (cGy)                                                                   2,997.00±2.82                                                3,300.00±3.12         3,285.00±3.13                                             3,083.00±3.07
  Lung all V5^e^ (%)                                                                      49.59±0.04                                                   50.14±0.05            49.82±0.05                                                50.03±0.05
  Lung all V10^e^ (%)                                                                     27.66±0.02                                                   33.3±0.03             31.89±0.03                                                28.23±0.02
  Lung all V20^e^ (%)                                                                     14.83±0.01                                                   15.25±0.01            15.28±0.02                                                15.01±0.02
  Lung all V30^e^ (%)                                                                     11.90±0.01                                                   11.70±0.01            11.99±0.01                                                12.17±0.01
  Lung all D mean (cGy)                                                                   1,071.10±1.02                                                1,122.40±1.01         1,136.00±1.01                                             1,083.70±1.02
  Lung-ipsilateral D mean (cGy)                                                           1,843.80±1.71                                                1,892.50±1.79         1,918.20±1.91                                             1,873.50±1.81
  Lung-ipsilateral V5 (%)                                                                 53.72±0.05                                                   53.68±0.04            52.36±0.04                                                52.76±0.04
  Lung-ipsilateral V10 (%)                                                                47.45±0.04                                                   48.38±0.04            47.69±0.04                                                47.51±0.04
  Lung-ipsilateral V20 (%)                                                                33.38±0.03                                                   34.74±0.03            34.59±0.03                                                34.73±0.03
  Lung-ipsilateral V30 (%)                                                                27.54±0.02                                                   27.08±0.02            27.76±0.02                                                28.17±0.02
  Lung-contralateral D mean (cGy)                                                         479.90±0.46                                                  531.20±0.52           537.00±0.53                                               481.20±0.47^[c](#tfn6-ol-0-0-7732){ref-type="table-fn"}^
  Lung-contralateral V5 (%)                                                               46.05±0.04                                                   46.97±0.04            47.62±0.04                                                47.72±0.04
  Lung-contralateral V10                                                                  12.43±0.01                                                   21.42±0.02            19.77±0.01                                                13.61±0.01^[c](#tfn6-ol-0-0-7732){ref-type="table-fn"}^
  Lung-contralateral V20                                                                  0.72±0.00                                                    0.43±0.00             0.60±0.00                                                 0.00±0.00
  Lung-contralateral V30                                                                  0.00±0.00                                                    0.00±0.00             0.00±0.00                                                 0.00±0.00
  HI                                                                                      0.11±0.00                                                    0.16±0.00             0.18±0.00                                                 0.09±0.00
  CI                                                                                      0.66±0.00                                                    0.51±0.00             0.49±0.00                                                 0.70±0.00

P\<0.05 compared with 2PA-VMAT plan

P\<0.05 compared with SA-VMAT plan

P\<0.05 compared with SA-VMAT plan. IMRT, intensity-modulated radiation therapy; VMAT, volumetric modulated arc therapy; SA, single arc; PA, partial arc; 2PA, double partial arc; SD, standard deviation; PTV, planning target volume; cGy, centigray; HI, homogeneity index; CI, conformity index.

###### 

Dosage comparison between VMAT and IMRT plans in central lung cancer in which the target volume encompassing the mediastinal lymphatic drainage region.

  PTV encompassing the mediastinal lymphatic drainage region in central lung cancer   IMRT (mean ± SD)                                             SA-VMAT (mean ± SD)   PA-VMAT (mean ± SD)                                       2PA-VMAT (mean ± SD)
  ----------------------------------------------------------------------------------- ------------------------------------------------------------ --------------------- --------------------------------------------------------- ------------------------------------------------------------
  PTV Dmax                                                                            7,063.70±7.05^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^   7,689.30±7.65         7,651.10±7.55                                             7,644.10±7.55
  PTV Dmin                                                                            4,576.80±4.55                                                4,539.10±4.53         4,325.10±4.37                                             4,368.30±4.38
  PTV D100 (cGy)                                                                      4,576.80±4.56                                                4,539.10±4.51         4,325.10±4.31                                             4,368.30±4.37
  PTV D mean (cGy)                                                                    6,473.90±6.50^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^   6,875.30±6.79         6,847.40±6.83                                             6,725.90±6.71
  PTV D98 (cGy)                                                                       5,800.00±5.79                                                5,800.00±5.78         5,720.00±5.72                                             5,720.00±5.72
  PTV D95 (cGy)                                                                       6,000.00±5.58                                                6,000.00±5.69         6,000.00±5.90                                             6,000.00±5.68
  PTV D50 (cGy)                                                                       6,513.00±6.37^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^   6,950.00±6.68         6,948.00±6.78                                             6,792.00±6.68^[c](#tfn9-ol-0-0-7732){ref-type="table-fn"}^
  PTV D2 (cGy)                                                                        6,782.00±6.34^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^   7,501.00±7.24         7,350.00±7.15                                             7,198.00±7.03^[c](#tfn9-ol-0-0-7732){ref-type="table-fn"}^
  Heart V30^e^ (%)                                                                    43.07±0.04                                                   36.11±0.03            42.25±0.04                                                42.66±0.04^[c](#tfn9-ol-0-0-7732){ref-type="table-fn"}^
  Heart V40^e^ (%)                                                                    31.42±0.03                                                   22.42±0.02            28.39±0.02                                                34.3±0.03^[c](#tfn9-ol-0-0-7732){ref-type="table-fn"}^
  Spinalcord D max (cGy)                                                              4,380.3±4.37^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^    4,947.4±4.87          5,039.6±5.37                                              4,515.5±4.29^[c](#tfn9-ol-0-0-7732){ref-type="table-fn"}^
  Spinalcord D~5~ (cGy)                                                               3,763.00±3.39                                                4,098.00±4.01         4,175.00±4.12                                             3,976.00±3.97
  Lung all V5^e^ (%)                                                                  74.67±0.07                                                   77.31±0.07            76.43±0.07                                                75.93±0.07
  Lung all V10^e^ (%)                                                                 63.72±0.06                                                   70.70±0.07            67.66±0.06^[b](#tfn8-ol-0-0-7732){ref-type="table-fn"}^   64.11±0.06^[c](#tfn9-ol-0-0-7732){ref-type="table-fn"}^
  Lung all V20^e^ (%)                                                                 35.22±0.03                                                   44.19±0.04            38.47±0.03^[b](#tfn8-ol-0-0-7732){ref-type="table-fn"}^   35.18±0.03^[c](#tfn9-ol-0-0-7732){ref-type="table-fn"}^
  Lung all V30^e^ (%)                                                                 20.54±0.02^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^      22.06±0.02            23.02±0.02                                                21.51±0.02
  Lung all D mean (cGy)                                                               1,869.40±1.78                                                2,034.40±2.02         1,968.50±1.98                                             1,913.00±1.99^[c](#tfn9-ol-0-0-7732){ref-type="table-fn"}^
  Lung-ipsilateral D mean (cGy)                                                       33.77±0.03^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^      37.08±0.03            41.03±0.03^[b](#tfn8-ol-0-0-7732){ref-type="table-fn"}^   37.26±0.03
  Lung-ipsilateral V5 (%)                                                             80.64±0.08                                                   82.49±0.08            80.57±0.08                                                80.69±0.08
  Lung-ipsilateral V10 (%)                                                            75.11±0.07                                                   75.91±0.07            73.95±0.07                                                75.55±0.07
  Lung-ipsilateral V20 (%)                                                            54.19±0.05                                                   58.49±0.05            58.27±0.05                                                54.60±0.05
  Lung-ipsilateral V30 (%)                                                            33.77±0.03^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^      37.08±0.03            41.03±0.03                                                37.26±0.03
  Lung-contralateral D mean (cGy)                                                     1,483.70±1.37                                                1,751.90±1.67         1,540.60±1.56                                             1,446.40±1.46
  Lung-contralateral V5 (%)                                                           80.07±0.08^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^      86.34±0.08            86.47±0.08                                                84.96±0.08
  Lung-contralateral V10                                                              62.49±0.06                                                   78.42±0.07            73.59±0.07                                                63.57±0.06^[c](#tfn9-ol-0-0-7732){ref-type="table-fn"}^
  Lung-contralateral V20                                                              20.67±0.02                                                   36.62±0.03            23.61±0.02                                                20.11±0.02
  Lung-contralateral V30                                                              9.60±0.00                                                    9.42±0.00             7.18±0.00                                                 7.95±0.00
  HI                                                                                  0.15±0.00^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^       0.24±0.00             0.23±0.00                                                 0.22±0.00
  CI                                                                                  0.70±0.00^[a](#tfn7-ol-0-0-7732){ref-type="table-fn"}^       0.70±0.00             0.61±0.00                                                 0.58±0.00^[c](#tfn9-ol-0-0-7732){ref-type="table-fn"}^

P\<0.05 compared with 2PA-VMAT plan

P\<0.05 compared with SA-VMAT plan

P\<0.05 compared with SA-VMAT plan. IMRT, intensity-modulated radiation therapy; VMAT, volumetric modulated arc therapy; SA, single arc; PA, partial arc; 2PA, double partial arc; SD, standard deviation; PTV, planning target volume; cGy, centigray; HI, homogeneity index; CI, conformity index.
